REGN · Insider Trading
Regeneron Pharmaceuticals Inc
Every open-market purchase and sale reported by REGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Andrew J Murphy | Co-Chief Scientific Officer | MIXED | — | −$6.41M |
| 2026-09-03 | Kathryn Guarini | Director | MIXED | — | −$52.25K |
| 2026-09-03 | Marion McCourt | EVP Commercial | Sell | −2,346 | −$2.00M |
| 2026-08-21 | Joseph J Larosa | EVP General Counsel and Secret | MIXED | +3,263 | −$2.80M |
| 2026-08-20 | Christopher R. Fenimore | EVP Finance CFO | MIXED | +1,684 | −$1.34M |
| 2026-08-12 | Huda Y Zoghbi | Director | MIXED | — | −$338.65K |
| 2026-08-12 | Kathryn Guarini | Director | MIXED | — | −$32.25K |
| 2026-07-07 | Arthur F Ryan | Director | Sell | −200 | −$130.03K |
| 2026-05-04 | Arthur F Ryan | Director | Sell | −100 | −$70.52K |
| 2026-04-03 | Arthur F Ryan | Director | Sell | −100 | −$77.73K |
| 2026-03-03 | Arthur F Ryan | Director | Sell | −100 | −$78.55K |
| 2026-02-23 | Huda Y Zoghbi | Director | MIXED | — | −$662.79K |
| 2026-02-11 | Arthur F Ryan | Director | Sell | −100 | −$77.85K |
| 2026-02-11 | Jason Pitofsky | SVP Controller | MIXED | −1,036 | −$1.09M |
| 2026-01-08 | Bonnie L Bassler | Director | MIXED | — | −$638.82K |
| 2026-01-06 | Christine A Poon | Director | A | +155 | — |
| 2026-01-06 | Bonnie L Bassler | Director | A | +155 | — |
| 2026-01-06 | Michael S Brown | Director | A | +155 | — |
| 2026-01-06 | N Anthony Coles | Director | A | +155 | — |
| 2026-01-06 | Arthur F Ryan | Director | A | +155 | — |
| 2026-01-06 | Joseph L Goldstein | Director | A | +155 | — |
| 2026-01-06 | David P Schenkein | Director | A | +155 | — |
| 2026-01-06 | Kathryn Guarini | Director | A | +155 | — |
| 2026-01-06 | George L Sing | Director | A | +155 | — |
| 2026-01-06 | Craig B. Thompson | Director | A | +155 | — |
| 2026-01-06 | Huda Y Zoghbi | Director | A | +155 | — |
| 2026-01-05 | Leonard S Schleifer | Bd. Co-Chair, President & CEO | MIXED | — | −$22.06M |
| 2026-01-05 | George Yancopoulos | Bd. Co-Chair, President & CSO | MIXED | — | −$22.06M |
| 2025-12-31 | George L Sing | Director | MIXED | +3,024 | +$634 |
| 2025-12-11 | Leonard S Schleifer | Bd. Co-Chair, President & CEO | MIXED | +17,578 | −$12.86M |
| 2025-12-11 | George Yancopoulos | Bd. Co-Chair, President & CSO | MIXED | +14,941 | −$10.93M |
| 2025-12-11 | Marion McCourt | EVP Commercial | F | −1,021 | −$716.24K |
| 2025-12-11 | Andrew J Murphy | EVP Research | F | −4,229 | −$2.97M |
| 2025-12-11 | Daniel P Van Plew | EVP & General Mgr, Industrial | F | −2,552 | −$1.79M |
| 2025-12-09 | Christopher R. Fenimore | EVP Finance CFO | MIXED | +2,035 | −$707.24K |
| 2025-12-09 | Joseph J Larosa | EVP General Counsel and Secret | MIXED | +1,080 | −$995.26K |
| 2025-12-09 | Marion McCourt | EVP Commercial | MIXED | +1,140 | −$952.49K |
| 2025-12-09 | Andrew J Murphy | EVP Research | MIXED | +2,016 | −$1.21M |
| 2025-12-09 | Daniel P Van Plew | EVP & General Mgr, Industrial | MIXED | +1,809 | −$1.36M |
| 2025-12-09 | Jason Pitofsky | VP Controller | MIXED | +1,075 | −$705.10K |
| 2025-11-24 | Bonnie L Bassler | Director | MIXED | — | −$287.74K |
| 2025-11-24 | Joseph J Larosa | EVP General Counsel and Secret | MIXED | +1,764 | −$1.32M |
| 2025-11-10 | Jason Pitofsky | VP Controller | Sell | −431 | −$280.77K |
| 2025-10-31 | Andrew J Murphy | EVP Research | MIXED | +972 | −$1.63M |
| 2025-10-31 | Christine A Poon | Director | MIXED | +2,712 | +$537.59K |
| 2025-01-06 | Bonnie L Bassler | Director | A | +166 | — |
| 2025-01-06 | Michael S Brown | Director | A | +166 | — |
| 2025-01-06 | Joseph L Goldstein | Director | A | +166 | — |
| 2025-01-06 | Kathryn Guarini | Director | A | +166 | — |
| 2025-01-06 | Christine A Poon | Director | MIXED | +180 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| George Yancopoulos | Bd. Co-Chair, President & CSO | 510,460 | $415.14M |
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | 370,577 | $301.38M |
| Neil Stahl | EVP Research and Development | 53,434 | $43.46M |
| Andrew J Murphy | Co-Chief Scientific Officer | 52,760 | $42.91M |
| Joseph J Larosa | EVP General Counsel and Secret | 45,805 | $37.25M |
| Daniel P Van Plew | EVP & General Mgr, Industrial | 34,049 | $27.69M |
| George L Sing | Director | 31,407 | $25.54M |
| Christopher R. Fenimore | EVP Finance CFO | 24,608 | $20.01M |
| Arthur F Ryan | Director | 17,303 | $14.07M |
| Marion McCourt | EVP Commercial | 12,222 | $9.94M |
| Michael S Brown | Director | 7,865 | $6.40M |
| Joseph L Goldstein | Director | 6,703 | $5.45M |
| Christine A Poon | Director | 5,219 | $4.24M |
| Jason Pitofsky | SVP Controller | 4,712 | $3.83M |
| Huda Y Zoghbi | Director | 2,503 | $2.04M |
| N Anthony Coles | Director | 1,714 | $1.39M |
| Bonnie L Bassler | Director | 1,703 | $1.38M |
| Kathryn Guarini | Director | 1,003 | $815.71K |
| Craig B. Thompson | Director | 775 | $630.28K |
| David P Schenkein | Director | 603 | $490.40K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the REGN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.